Rezvilutamide

Rezvilutamide

Clinical data
Other names	SHR3680
Drug class	Nonsteroidal antiandrogen
Identifiers
IUPAC name 4-[3-[4-[(2S)-2,3-dihydroxypropoxy]phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
CAS Number	1572045-62-5
PubChem CID	89995232
UNII	70FJN2AW22
CompTox Dashboard (EPA)	DTXSID001336581
Chemical and physical data
Formula	C22H20F3N3O4S
Molar mass	479.47 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1(C(=O)N(C(=S)N1C2=CC=C(C=C2)OC[C@H](CO)O)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
InChI InChI=1S/C22H20F3N3O4S/c1-21(2)19(31)27(15-4-3-13(10-26)18(9-15)22(23,24)25)20(33)28(21)14-5-7-17(8-6-14)32-12-16(30)11-29/h3-9,16,29-30H,11-12H2,1-2H3/t16-/m0/s1 Key:KRBMOYIWQCZVHA-INIZCTEOSA-N

Rezvilutamide (INN Tooltip International Nonproprietary Name), ^{[1] [2]} sold under the brand name Ariane, is a nonsteroidal antiandrogen which is approved for the treatment of prostate cancer in China and is or was under development for the treatment of breast cancer. ^{[3] [4] [5]} It is a selective androgen receptor antagonist with reduced brain distribution compared to the structurally related nonsteroidal antiandrogen enzalutamide. ^{[3] [5]} The drug was developed by Jiangsu Hengrui Medicine. ^[3] Other structural analogues of rezvilutamide that are also used as antiandrogens besides enzalutamide include apalutamide and proxalutamide.

References

1. "Rezvilutamide". chemidplus. U.S. National Library of Medicine.
2. "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO.
3. "SHR 3680". AdisInsight.
4. Keam SJ (January 2023). "Rezvilutamide: First Approval". Drugs. 83 (2): 189–193. doi:10.1007/s40265-022-01831-y. PMID   36630077. S2CID   255593586.
5. Qin X, Han W, Luo H, Du C, Zou Q, Sun Z, et al. (2020). "SHR3680, a novel antiandrogen, for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A phase I/II study". Journal of Clinical Oncology. 38 (6_suppl): 90. doi:10.1200/JCO.2020.38.6_suppl.90. S2CID   214027454.